我国就《疫苗管理法》公开向社会征求意见

Vaccine producers could be given harsh penalties for a range of violations, with substantial fines possible, under a new draft law from China's top market regulator after a major quality control scandal earlier this year.

在今年早些时候发生重大疫苗质检丑闻之后，中国最高市场管理部门近日公布了一项新法律草案：疫苗生产商将因一系列违规行为受到严厉惩罚，还可能面临高额罚款。

The State Administration for Market Regulation released the draft of a vaccine management law to solicit public opinions last Sunday.

上周日，国家市场监督管理总局发布《疫苗管理法（征求意见稿）》向公众征集意见。

Serious violators could have profits confiscated, certificates revoked, production suspended and face fines of up to 10 times the value of the products in question.

严重违规者将被没收利益所得、撤销许可证、停产，最高将面临问题产品货值金额10倍的罚款。

Violations under scrutiny include falsifying manufacturing records and failing to recall products sold after quality issues or other potential safety risks were discovered, according to the draft.

根据该意见稿，须接受监督的违规行为包括篡改生产记录、对发现存在质量问题或其他潜在安全风险的产品未予以召回等。

Senior executives and other employees at key posts within offending companies will have their salaries recalled during periods of infraction, and may be required to pay an additional fine of between 50-100% of their pay.

违规企业高管和关键岗位人员将被没收其在违法期间自本单位所获收入，并可能处以收入50%以上、一倍以下的罚款。

They may be banned from engaging in pharmaceutical activities for life, according to the draft.

该意见稿称，这些人还可能被终身禁止从事药品相关活动。